title: Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.
abstract: Adenosine A(2A) receptor (A(2A)R) antagonists are being investigated as promising treatment strategy for Parkinson's disease (PD). To test whether A(2A)R antagonists are beneficial in early PD stages we used MitoPark mice, a genetic model with gradual degeneration of DA cells. Daily treatment of young MitoPark mice for eight weeks with the A(2A)R antagonist MSX-3 prevented the reduction of spontaneous locomotor activity observed in saline or L-DOPA treated animals. Chronic A(2A)R antagonist treatment neither induced desensitization of receptors nor accumulation of the drug in brain tissue. Despite beneficial effects on behavior, which are not improved upon addition of a low dose of L-DOPA, the characteristic decline of dopamine levels was not changed. Our results indicate that effective dosing with A(2A)R antagonists should be tested as monotherapy in early PD, and serves to remind us that positive behavioral effects of such treatment need not be reflected in rescue of striatal dopamine levels.
authors.affiliation: Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Daniel
authors.initials: D
authors.lastname: Marcellino
authors.forename: Eva
authors.initials: E
authors.lastname: Lindqvist
authors.forename: Marion
authors.initials: M
authors.lastname: Schneider
authors.forename: Christa E
authors.initials: CE
authors.lastname: Müller
authors.forename: Kjell
authors.initials: K
authors.lastname: Fuxe
authors.forename: Lars
authors.initials: L
authors.lastname: Olson
authors.forename: Dagmar
authors.initials: D
authors.lastname: Galter
mesh_terms: D058917:Adenosine A2 Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D007980:Levodopa / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014970:Xanthines / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D015259:Dopamine Agents; C113602:MSX 3 compound; D014970:Xanthines; D007980:Levodopa; D004298:Dopamine